PA
FRTX

Parallel Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Parallel Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6
Closed -$3K – 2156
2017
Q3 		$3K Buy
+6
New +$4.74K ﹤0.01% 1786

Other funds holding FRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Parallel Advisors's FRTX Position: Q4 2017 in Review

Parallel Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2017, closing a stake of 6 shares — an estimated $3K sold.

Parallel Advisors first reported a position in FRTX in Q3 2017 and held it in 1 quarter. The position peaked at $3K in Q3 2017. 31 funds tracked by Wall St. Rank hold FRTX as of Q4 2017.

  • Parallel Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Parallel Advisors sold 6 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $3K.
  • Parallel Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Parallel Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $3K in Q3 2017.
  • 31 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Parallel Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.